Clinical Trial Update: A Clinical Trial of AP026 (TQA2226) for Injection in Adult Subjects. [Phase 1]

View source ↗

Summary

Phase 1 trial of AP026 (TQA2226) for injection in adults with Type 2 diabetes mellitus has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• AP026 (TQA2226)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Diabetes Mellitus, Type 2 | Phase 1 | Status: TERMINATED